Clinical and Experimental Hepatology

Abstract

1/2020 vol. 6
Report

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report

Anna Piekarska 1
,
Aleksandra Berkan-Kawińska 1
,
Zbigniew Deroń 2
,
Justyna Ciupińska 2
,
Jolanta Białkowska 1
  1. Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland
  2. Department of Infectious Diseases and Liver Diseases, WSSz Bieganski, Lodz, Poland
Clin Exp HEPATOL 2020; 6, 1: 60–62
DOI: https://doi.org/10.5114/ceh.2020.93059
Online publish date: 2020/02/17
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Aim of the study

The aim of this overview was to evaluate the efficacy of sofosbuvir/velpatasvir (SOF/VEL) combination in a real-life setting, with particular regard to treatment-experienced individuals.

Material and methods

Seventy-five consecutive patients who were treated with SOF/VEL, completed the 12-week follow-up and had sustained virologic response (SVR) evaluated were included in the analysis. Out of them, 60 (80%) patients were treatment-naïve and 15 (20%) were treatment-experienced.

Results

SVR rates reached 89.4% (66/75) in the whole study group and were comparable irrespective of the fibrosis stage or HCV genotype. However, a significant difference in treatment efficacy between treatment-naïve and treatment-experienced individuals was observed, with SVR rates of 98.3% (59/60) and 46.7% (7/15), respectively (p < 0.0001).

Conclusions

Further studies including large real-life cohorts of treatment-experienced patients treated with SOF/VEL are warranted to elucidate the real efficacy of this regimen as a retreatment option.

Keywords

retreatment, chronic hepatitis C, velpatasvir/sofosbuvir

Share
Coverage in
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications